Researchers from Italy have uncovered the reason behind a remarkable medical anomaly: why the heart, through which blood courses every minute, is extraordinarily resistant to cancerous development. It turns out that the very mechanical action of this vital organ—its ceaseless contractions—physically inhibits cancerous cells from establishing themselves and proliferating. However, the explanation extends beyond mere mechanics.
This finding, detailed in the journal Science late last April, paves the way for a completely novel form of cancer intervention: “mechanical therapy” against malignancy.
The Heart’s Hidden Secret
Primary heart cancer is exceptionally rare, diagnosed in fewer than two individuals out of every hundred thousand. For years, scientists debated whether this rarity was linked to its distinctive blood supply or the specific cell types involved. A research team led by Serena Zacchini at the International Centre for Genetic Engineering and Biotechnology in Trieste (Italy) proposed a new hypothesis: the constant mechanical strain experienced by the cardiac muscle is the key factor.
To test this, the scientists transplanted lung cancer cells into the hearts of laboratory mice. When the rodents’ hearts beat normally, the tumors displayed virtually no growth. Yet, when the organ was surgically “unloaded,” relieving it of the intense work of pumping blood, the cancer began to advance rapidly.
The same outcome was confirmed in cell culture experiments: simulating mechanical compression suppressed tumor growth, whereas its absence encouraged it.
The scientific discovery underpinning this method has been awarded the Nobel Prize.
What makes this unique? In Moscow, they’ve started producing a drug for 13 types of cancer.
Learn more
The Protein That Keeps Tumors in Check
The primary “actor” in this process has been identified as the protein Nesprin-2—a kind of “antenna” situated on the nuclear envelope of the cell. It possesses the ability to sense mechanical force and translate it into a chemical signal that alters gene expression.
The series of events, in simplified terms, unfolds like this:
The heart contracts, generating mechanical stress across all its cells.
The Nesprin-2 protein detects this “squeezing.”
Inside the cell nuclei, epigenetic modifications are initiated, which switch off the genes responsible for tumor proliferation and division.
Consequently, cancer cells essentially lose their capacity to multiply.
When scientists genetically disabled Nesprin-2 in samples of beating hearts, the protective effect vanished immediately, allowing the tumor to grow. This confirmed that the core element of the mechanism had been found.
Andrey Artamonov’s work is meticulous. Whether his cells can produce the drug depends entirely on how precisely he sets the environmental conditions.
Caging Cancer. Russia is developing medications against devastating diseases.
Learn more
Can Other Tumors Be “Shaken”?
A crucial takeaway from the study is that this mechanism appears to be universal. Serena Zacchini’s team examined tissue samples from patients afflicted with lung, colon, or skin cancer that had metastasized to the heart and other organs. The epigenetic signature of tumor suppression proved consistent across various cancer types.
“This is the first time we’ve observed mechanical forces exterior to the tumor itself influencing its growth. We aim to utilize this knowledge to develop mechanical cancer therapy,” Zacchini told Live Science.
Researchers now face the ambitious challenge of replicating the “heart’s rhythm” in other parts of the body. They are developing specialized, adjustable actuators (devices converting electrical or other energy into linear motion) that could be affixed to the surface of tumors, such as metastatic lesions on the skin. This device would mimic the frequency and force of cardiac beats, attempting to trick cancer cells into a state of dormancy.
According to the researchers, initial clinical trials involving humans could commence within the next four years.
From Cautious Optimism to Future Treatment
Julie Filippi, Chair of Cardiothoracic Surgery and Director of the Cardiovascular Research Laboratory at the University of Pittsburgh, deems the findings “extremely significant.” However, she cautions that substantial work remains; scientists need a clearer understanding of how the properties of tissues surrounding cancer cells affect their sensitivity to mechanical forces.
The paramount concern here remains safety. Serena Zacchini herself admits: “My greatest worry is that by compressing the tumor, we might inadvertently facilitate its spread. We must entirely eliminate that risk before moving forward.”
In addition to employing dedicated mechanical devices, scientists are also pursuing a pharmacological pathway for cancer treatment—medications capable of triggering the same epigenetic modifications within the tumor as the heart does, but without physical intervention.
If this approach proves both effective and safe, oncologists could gain access to a fundamentally new, non-drug-based method for combating this fatal disease. What nature has utilized for millions of years to safeguard our most crucial organ might someday serve to protect the entire body.
About the Author
